PART B -FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (573) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

Note: A certificate of mailing on only be used for domestic mailings of the Followship of the Policy State of the Company of t	notifications.		·	espondence address, and/or	(b) indicating a separate FEE	ADDRESS for maintenance fee	
WOMBLE CARLYLE SANDRIDGE & RICE, PLLC ATTIN: PATENT DOCKETING 32°0 FLOOR P.O. Box 7037 Atlanta, GA 30357-0037 August 9, 2006 AUGUST BERNAMED IN VENTIOR CANCER SPECIFIC MONOCLONAL ANTIBODIES APPLY. TYPE MALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional yes EXAMINER ART UNIT CLASS SUBJECTASS Not Yet Assigned NA 1. CLange of correspondence address or indication of Fee Address ("A CFR 1,363.") Change of correspondence address or indication of Fee Address ("A CFR 1,363.") Change of correspondence address or indication of Fee Address ("A CFR 1,363.") Change of correspondence address (or Change of Correspondence address for FEO \$81/22) attached. The Address findeation for Fee Address findeation for Fee Address findeation for Fee Address findeation for Fee Address ("A CFR 1,363.") Correspondence address for FEO \$81/22) attached. The Address findeation for Fee Address findeatio	CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)				Note: A certificate of mailing can only be used for domestic mailings of the		
NOMBLE CARLYLE SANDRIDGE & RICE, PLLC ATTIN, PATENT DOCKETING 32**0 FLOOR P.O. Box 7037 Allanta, GA 30357-0037 Al	26158 7590	03-09-2009			Fee(s) Transmittal. This certificate cannot be used for any other accompanying		
P.O. Box 7037 Atlanta, GA 30357-0037 Atlanta,	WOMBLE CARLYLE	E SANDRIDGE & RICE,	, PLLC		certificate of mailing or transmiss	sion.	
States Postal Service with sufficient possage for first class mail in an envelope addressed to the Mail Stop ISSUE address above, for being fleshing transmitted to the USPTO (571) 273-2885, on the date indicated below. Depositor's name Comparison	ATTN: PATENT DOO	CKETING 32 ND FLOOR					
addressed to the Mail Stop ISSUE FEE address above, or being facishmic transmitted to the USPTO (571) 273-2885, on the date indicated below. [Dependent name] [Objective name]		•					
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10:554.321 August 9, 2006 Le Sun A256 1030US 4564 TITLE OF INVENTION: CANCER SPECIFIC MONOCLONAL ANTIBODIES APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(5) DUE DATE DUE nonprovisional yes \$755.00 \$300.00 \$1,055.00 June 9, 2009 EXAMINER ART UNIT CLASS-SUBCLASS NOT VER Assigned from 10:505.847, Rev 03-200 archere cerel rathered from 10:505.847, Rev 03-200 archered from 10:505.847, Rev 03-200,	Atlanta, GA 30357-00	37		States Postai	the Mail Stop ISSUE FEE ad	or first class mail in an envelope	
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10:554.321 August 9, 2006 LC Sun A256 1050US 4564 TITLE OF INVENTION: CANCER SPECIFIC MONOCLONAL ANTIBODIES APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional yes \$755.00 \$300.00 \$1,055.00 June 9, 2009 EXAMINER ART UNIT CLASS-SUBCLASS NOT YET Assigned N/A 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.361). "Fee Address" indication or "Fee Address" Indication from PTO/SB472, Rev 03-02 or more recent) attacked. Use of a Customer Number is required. Use of a Customer Number is required. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee as identified below, no assignee datus will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) 4. & G Phanmaccutical, Inc. Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27 (graz). Authorized Signature Deposit Account Number Detection, a required attorney or agent, or the assignee or other party in morest as shown by the records of the United States Patent and Tylemark Office.				transmitted to	the USPTO (571) 273-2885, on the USPTO (571)	he date indicated below.	
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10:554.321 August 9, 2006 Le Sun A256 10:50US 45:64 TITLE OF INVENTION: CANCER SPECIFIC MONOCLONAL ANTIBODIES APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional yes \$755.00 \$300.00 \$1,055.00 June 9, 2009 EXAMINER ART UNIT CLASS-SUBCLASS Not Yet Assigned NA 1. Change of correspondence address or indication of 'Fee Address' (37 CFR 1:363). Change of correspondence address (or Change of Correspondence Address of Indication (or 'Fee Address' Indication (or 'Fee A							
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR AZ56 1050US 4564 TITLE OF INVENTION: CANCER SPECIFIC MONOCLONAL ANTIBODIES APPLN: TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional yes \$755.00 \$300.00 \$1,055.00 June 9, 2009 EXAMINER ART UNIT CLASS-SUBCLASS Not Yet Assigned N/A 1. Change of correspondence address or indication of "Fee Address" (7 CFR 1.363). Change of correspondence address (or Change of Correspondence address from PTO/SE/2) attached. "Fee Address" (7 CFR 1.363). Change of correspondence address from PTO/SE/2) attached. "Fee Address" indication (or "Fee Address" Indication from PTO/SB/47; Rev 0.3-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless on assigne is identified below, no assignee date will appear on the patent from its process of the printed of the patent for fling an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) 4. G. Opharmaceutical, Inc. Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Publication Fee (No small entity discount permitted) Advance Order -# of Copies X The Director is hereby authorized by charge the required feets), or credit any overpayment, to Deposit Account Number 99-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to a purply the Issue Fee and Publication Fee (if any) er to re-apply any previously paid issue fee to the applicantion identified above. Authorized Signature Date Date Date Date Date Date Date Date Due DATE DUE DATE DUE DATE DUE DATE DUE DATE DUE DA					*		
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional yes \$755.00 \$300.00 \$1,055.00 June 9,2009 EXAMINER ART UNIT CLASS-SUBCLASS Not Yet Assigned N/A 1. Change of correspondence address or indication of "Fee Address" indication of "Fee Address" indication of "Fee Address" indication for proposed as indication for the patent for patent for patent for fine an assignment in the patent for patent	APPLICATION NO.	FILING DATE	FIRST NAM	IED INVENTOR	ATTORNEY DOCKET NO.		
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional yes \$755.00 \$300.00 \$1,055.00 June 9, 2009 EXAMINER ART UNIT CLASS-SUBCLASS Not Yet Assigned N/A 1. Change of correspondence address or indication of "Fee Address" (17 FER 1363). Change of correspondence address or indication of "Fee Address" indication of the Patent of Pee Address indication of the	10/554,321	August 9, 2006	L	e Sun	A256 1050US	4564	
Nonprovisional yes	TITLE OF INVENTIO	N: CANCER SPEC	IFIC MONOCLONAL ANT	TIBODIES .			
EXAMINER	APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
Not Yet Assigned Not Address' (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address' indication (or "Fee Address' Indication Indication (or "Fee Address' Indication Indic	nonprovisional	yes	\$755.00	\$300.00	\$1,055.00	June 9, 2009	
Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).	L		ART UNIT	CLASS-SUBCLASS			
Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication from PTO/SB/122) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE A & G Pharmaceutical, Inc. (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Pharmaceutical, Inc. (Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Publication Fee (No small entity discount permitted) Advance Order # of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trylemark Office.							
Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Phanmaceutical, Inc. Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: A check in the amount of the fee(s) is enclosed. X Publication Fee (No small entity discount permitted) Advance Order # of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) A Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Typlemark Office.				ing on the patent front page	, list Womble Ca	rlyle Sandridge & Rice	
Correspondence Address form PTO/SB/1/22) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. "Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filling an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Pharmaceutical, Inc. Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. X Publication Fee (No small entity discount permitted) Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number Deposit Account Number 5. Change in Entity Status (from status indicated above) a Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. B Applicant; a registered automey or agents, and the names of a patent attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Tracemark Office.	(1) the mannes of up to a registered patent						
"Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Pharmaceutical, Inc. Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. X Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order # of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Tracemark Office.			22) attached. (2) the name	e of a single firm (having a	s a member 2		
form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Pharmaceutical, Inc. Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: A b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. Advance Order # of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trylemark Office.			ss" Indication a registered		e names of		
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Phanmaceutical, Inc. Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. X Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number Op-0528 (cnclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trydemark Office.	form PTO/SB/4	7; Rev 03-02 or more rec	ent) attached. up to 2 regi				
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Phannaceutical, Inc. , Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. X Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trafemark Office. Date June 8, 2009			<u> </u>				
for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Pharmaceutical, Inc. , Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number O9-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Tratemark Office. Date June 8, 2009							
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) A & G Pharmaceutical, Inc. , Columbia, MD Please check the appropriate assignee category or categories (will not be printed on the patent):	for recordation as set	ess an assignee is identificated in 37 CFR 3.11. Co.	ed below, no assignee data w	vill appear on the patent. If	an assignee is identified below,	the document has been filed	
A & G Pharmaceutical, Inc. Please check the appropriate assignee category or categories (will not be printed on the patent):							
Please check the appropriate assignee category or categories (will not be printed on the patent):			(1)		u STATE OR COUNTRY)		
4a. The following fee(s) are enclosed: X Issue Fee	Please check the appropriat	te assignee category or catego	ories (will not be printed on the		Corporation or other private	Grown antity Covernment	
A check in the amount of the fee(s) is enclosed. X Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date June 8, 2009					X Corporation of other private	group entity Oovernment	
Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). See 37 CFR 1.27. Deposit Account is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).		are enclosed.		•	/-> f11		
Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trydemark Office. Date June 8, 2009	A Issue Fee		A che	ck in the amount of the rec	e(s) is enclosed.		
Deposit Account Number 09-0528 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trydemark Office. Date June 8, 2009	X Publication Fee	(No small entity discount	permitted) Payme	ent by credit card. Form P	ΓO-2038 is attached.		
5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Tratemark Office. Authorized Signature Date June 8, 2009	Advance Order -	# of Copies	X The D	X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to			
a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trydemark Office. Authorized Signature Date June 8, 2009			Depos	sit Account Number	09-0528 (enclose a	n extra copy of this form).	
The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trydemark Office. Authorized Signature Date June 8, 2009	5. Change in Entity Sta	atus (from status indicate	ed above)		·		
Authorized Signature Date June 8, 2009	a. Applicant clai	ms SMALL ENTITY sta	tus. See 37 CFR 1.27.	b. Applicant is no long	er claiming SMALL ENTITY st	atus. See 37 CFR 1.27(g)(2).	
	NOTE: The Issue Fee and	Publication Fee (if required	 d) will not be accepted from a 	(if any) or to re-apply any pr inyone other than the applic	eviously paid issue fee to the appliant; a registered attorney or agent;	cation identified above. ; or the assignee or other party in	
Typed or printed name V Lawrence J. Carroll Registration No. 40,940	Authorized Signatur	· Hand	all	*	Date	June 8, 2009	
	Typed or printed nat	ne V	Lawrence J. Carroll		Registration No.	40,940	